Request for Comments

Written comments and/or suggestions from the public and affected agencies are invited to address one or more of the following points: (1) Whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) The accuracy of the agency’s estimate of the burden of the proposed collection of information; including the validity of the methodology and assumptions used; (3) The quality, utility, and clarity of the information collected; and (4) Minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

FOR FURTHER INFORMATION CONTACT: To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact Charles, Hall, RPh, M.S., Chief, Pharmaceutical Management Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Executive Plaza North, Room 7149, 9000 Rockville Pike, Bethesda, Maryland 20891. Or call non-toll-free number 301–496–5725 or email your request, include your address to: hallch@mail.nih.gov.

Comments Due Date: Comments regarding this information collection are best assured of having their full effect if received within 60-days of the date of this publication.

Dated: September 14, 2012.

Vivian Horovitch-Kelley,
NCI Project Clearance Liaison, National Institutes of Health.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Human Genome Research Institute; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Human Genome Research Institute Special Emphasis Panel; R25 DAP Sept. 2012.
Date: October 25, 2012.
Time: 1 p.m. to 5 p.m.
Agenda: To review and evaluate grant applications.
Place: National Human Genome Research Institute, 5635 Fishers Lane, 3rd Floor Conference Room, Rockville, MD 20852 (Telephone Conference Call).

Contact Person: Keith McKenney, Ph.D., Scientific Review Officer, NHGRI, 5635 Fishers Lane, Suite 4076, Bethesda, MD 20814, 301–594–4280, mckkenneym@mail.nih.gov.

Name of Committee: National Human Genome Research Institute Special Emphasis Panel; Genomic Resources.
Date: October 29, 2012.
Time: 10 a.m. to 1 p.m.
Agenda: To review and evaluate grant applications.
Place: National Human Genome Research Institute, 5635 Fishers Lane, 4th floor Conference Room, Rockville, MD 20852 (Telephone Conference Call).

Contact Person: Keith McKenney, Ph.D., Scientific Review Officer, NHGRI, 5635 Fishers Lane, Suite 4076, Bethesda, MD 20814, 301–594–4280, mckkenneym@mail.nih.gov.

Name of Committee: National Human Genome Research Institute Initial Review Group; Genome Research Review Committee, GNOM–G (CEGS plus regular load).
Date: November 1–2, 2012.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant applications.
Place: National Human Genome Research Institute, 5635 Fishers Lane, Terrace Suite 9 & 10, Rockville, MD 20852.

(Catalogue of Federal Domestic Assistance Program Nos. 93.172, Human Genome Research, National Institutes of Health, HHS)

Dated: September 14, 2012.

David Clary,
Program Analyst, Office of Federal Advisory Committee Policy.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Center for Complementary & Alternative Medicine; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Center for Complementary and Alternative Medicine Special Emphasis Panel; Clinical Research of Complementary and Alternative Medicine.
Date: October 22, 2012.
Time: 1:30 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Two Democracy Plaza, 6707 Democracy Boulevard, Bethesda, MD 20892.

Contact Person: Hungyi Shau, Ph.D., Scientific Review Officer, National Center for Complementary and Alternative Medicine, National Institutes of Health, 6707 Democracy Boulevard, Suite 401, Bethesda, MD 20892, 301–402–1030, Hungyi.Shau@nih.gov.

For Complementary and Alternative Medicine, National Institutes of Health, HHS)

Dated: September 13, 2012.

Michelle Trout,
Program Analyst, Office of Federal Advisory Committee Policy.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the Board of Scientific Counselors, NHLBI.

The meeting will be closed to the public as indicated below in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The information collection and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Heart, Lung, and Blood Institute, NHLBI.
Date: October 25, 2012.
Time: 9 a.m. to 4 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20852.

(Catalogue of Federal Domestic Assistance Program Nos. 93.172, Human Genome Research, National Institutes of Health, HHS)

Dated: September 14, 2012.

David Clary,
Program Analyst, Office of Federal Advisory Committee Policy.

BILLING CODE 4140–01–P
with the provisions set forth in section 532h(c)(6), Title 5 U.S.C., as amended for the review, discussion, and evaluation of individual intramural programs and projects conducted by the National Heart, Lung, and Blood Institute, including consideration of personnel qualifications and performance, and the competence of individual investigators, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Board of Scientific Counselors, NHLBI.

Date: October 29, 2012.

Time: 9:00 a.m. to 5:00 p.m.

Agenda: To review and evaluate personal qualifications and performance, and competence of individual investigators.

Place: National Institutes of Health, Building 10, 10 Center Drive, Room B1D401, Bethesda, MD 20892.

Contact Person: Robert S. Balaban, Ph.D., Scientific Director, Division of Intramural Research, National Institutes of Health, NHLBI, Building 10, CRC, 4th Floor, Room 1581, 10 Center Drive, Bethesda, MD 20892, 301/496–2116.

Information is also available on the Institute’s/Center’s home page: www.nhlbi.nih.gov/meetings/index.htm, where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS)

Dated: September 13, 2012.

Michelle Trout,
Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2012–23127 Filed 9–19–12; 8:45 am]

BILLING CODE 4100–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of Refugee Resettlement

[CFDA Number 93.676]

Announcing the Award of 24 Single-Source Program Expansion Supplement Grants Under the Unaccompanied Alien Children’s Shelter Care Program

AGENCY: Office of Refugee Resettlement, ACF, HHS.

ACTION: The Office of Refugee Resettlement (ORR) announces the award of 24 single-source program expansion supplement grants under its Unaccompanied Alien Children’s (UAC) Program where grantees provide a range of custodial/residential shelter care and services for recently arrived unaccompanied alien children.

SUMMARY: The Administration for Children and Families (ACF), Office of Refugee Resettlement (ORR) announces the award of 24 single-source program expansion supplement grants for a total of $60,835,955. The additional funding provided to current grantees under ORR’s UAC program will support services to unaccompanied alien children through September 30, 2012.

The ORR UAC grantees that have received single-source program expansion supplements are:

<table>
<thead>
<tr>
<th>Grantee organization</th>
<th>Location</th>
<th>Award amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>BCFS Health and Human Services</td>
<td>San Antonio, TX</td>
<td>$24,765,693</td>
</tr>
<tr>
<td>BCFS Health and Human Services</td>
<td>San Antonio, TX</td>
<td>272,645</td>
</tr>
<tr>
<td>A New Leaf</td>
<td>Mesa, AZ</td>
<td>180,000</td>
</tr>
<tr>
<td>Bokenkamp</td>
<td>Corpus Christ, TX</td>
<td>547,826</td>
</tr>
<tr>
<td>Catholic Charities Miami (Boystown)</td>
<td>Miami, FL</td>
<td>752,203</td>
</tr>
<tr>
<td>Catholic Charities Galveston/Houston</td>
<td>Houston, TX</td>
<td>213,733</td>
</tr>
<tr>
<td>Children’s Village</td>
<td>Dobbs Ferry, NY</td>
<td>1,712,029</td>
</tr>
<tr>
<td>Children’s Village</td>
<td>Dobbs Ferry, NY</td>
<td>152,000</td>
</tr>
<tr>
<td>David and Margaret</td>
<td>LaVerne, CA</td>
<td>402,000</td>
</tr>
<tr>
<td>Florence Crittenton</td>
<td>Fullerton, CA</td>
<td>348,817</td>
</tr>
<tr>
<td>His House</td>
<td>Miami, FL</td>
<td>423,535</td>
</tr>
<tr>
<td>International Education Services</td>
<td>Los Fresnos, TX</td>
<td>2,260,821</td>
</tr>
<tr>
<td>International Education Services</td>
<td>Los Fresnos, TX</td>
<td>638,042</td>
</tr>
<tr>
<td>International Education Services</td>
<td>Los Fresnos, TX</td>
<td>192,577</td>
</tr>
<tr>
<td>Lutheran Immigration and Refugee Services (LIRS)</td>
<td>Baltimore, MD</td>
<td>1,836,754</td>
</tr>
<tr>
<td>Lutheran Immigration and Refugee Services (LIRS)</td>
<td>Baltimore, MD</td>
<td>268,612</td>
</tr>
<tr>
<td>Shenandoah Valley Children’s Center</td>
<td>Staunton, VA</td>
<td>135,000</td>
</tr>
<tr>
<td>Morrison Child and Family Services</td>
<td>Portland, OR</td>
<td>228,684</td>
</tr>
<tr>
<td>Pioneer Human Services</td>
<td>Tacoma, WA</td>
<td>135,257</td>
</tr>
<tr>
<td>YouthCare</td>
<td>Seattle, WA</td>
<td>322,080</td>
</tr>
<tr>
<td>Heartland Alliance</td>
<td>Chicago, IL</td>
<td>6,121,454</td>
</tr>
<tr>
<td>Southwest Key Inc.</td>
<td>Austin, TX</td>
<td>18,615,410</td>
</tr>
<tr>
<td>US Conference of Catholic Bishops (USCCB)</td>
<td>Washington, DC</td>
<td>182,855</td>
</tr>
<tr>
<td>US Committee on Refugees and Immigrants (USCRI)</td>
<td>Washington, DC</td>
<td>127,928</td>
</tr>
</tbody>
</table>


FOR FURTHER INFORMATION CONTACT: Kenneth Tota, Deputy Director, Office of Refugee Resettlement, Administration for Children and Families, 370 L’Enfant Promenade SW., Washington, DC 20447, Telephone (202) 401–4858.

SUPPLEMENTARY INFORMATION: The expansion supplement grants will support the expansion of bed capacity to meet the number of unaccompanied alien children referrals from the Department of Homeland Security (DHS). The funding program is mandated by Section 462 of the Homeland Security Act to ensure appropriate placement of all referrals from the DHS. The program is tied to DHS apprehension strategies and a sporadic number of border crossings.

